BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 32953521)

  • 1. Pulmonary oligometastases treated by stereotactic body radiation therapy (SBRT): a single institution's experience.
    Chai G; Yin Y; Zhou X; Hu Q; Lv B; Li Z; Shi M; Zhao L
    Transl Lung Cancer Res; 2020 Aug; 9(4):1496-1506. PubMed ID: 32953521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-response relationship with clinical outcome for lung stereotactic body radiotherapy (SBRT) delivered via online image guidance.
    Kestin L; Grills I; Guckenberger M; Belderbos J; Hope AJ; Werner-Wasik M; Sonke JJ; Bissonnette JP; Xiao Y; Yan D;
    Radiother Oncol; 2014 Mar; 110(3):499-504. PubMed ID: 24630539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes and toxicities in oligometastatic patients treated with stereotactic body radiotherapy for adrenal gland metastases: A multi-institutional retrospective study.
    Baydoun A; Chen H; Poon I; Badellino S; Dagan R; Erler D; Foote MC; Louie AV; Redmond KJ; Ricardi U; Sahgal A; Biswas T
    Clin Transl Radiat Oncol; 2022 Mar; 33():159-164. PubMed ID: 35243027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic Body Radiation Therapy for Pulmonary Oligometastases Arising from Non-lung Primaries in Patients Without Extrapulmonary Disease.
    Dohopolski MJ; Horne Z; Clump D; Burton SA; Heron DE
    Cureus; 2018 Feb; 10(2):e2167. PubMed ID: 29644155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A matched-pair analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer versus early stage non-small cell lung cancer.
    Wang X; Zamdborg L; Ye H; Grills IS; Yan D
    BMC Cancer; 2018 Oct; 18(1):962. PubMed ID: 30305131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic body radiotherapy of adrenal metastases-A dose-finding study.
    Buergy D; Würschmidt F; Gkika E; Hörner-Rieber J; Knippen S; Gerum S; Balermpas P; Henkenberens C; Voglhuber T; Kornhuber C; Barczyk S; Röper B; Rashid A; Blanck O; Wittig A; Herold HU; Brunner TB; Sweeney RA; Kahl KH; Ciernik IF; Ottinger A; Izaguirre V; Putz F; König L; Hoffmann M; Combs SE; Guckenberger M; Boda-Heggemann J
    Int J Cancer; 2022 Aug; 151(3):412-421. PubMed ID: 35383919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical results of mean GTV dose optimized robotic guided SBRT for liver metastases.
    Andratschke N; Parys A; Stadtfeld S; Wurster S; Huttenlocher S; Imhoff D; Yildirim M; Rades D; Rödel CM; Dunst J; Hildebrandt G; Blanck O
    Radiat Oncol; 2016 May; 11():74. PubMed ID: 27236333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors affecting local control of pulmonary oligometastases treated with stereotactic body radiotherapy.
    Sharma A; Duijm M; Oomen-de Hoop E; Aerts JG; Verhoef C; Hoogeman M; Nuyttens JJ
    Acta Oncol; 2018 Aug; 57(8):1031-1037. PubMed ID: 29488414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic body radiotherapy for adrenal oligometastasis in lung cancer patients.
    Arcidiacono F; Aristei C; Marchionni A; Italiani M; Fulcheri CPL; Saldi S; Casale M; Ingrosso G; Anselmo P; Maranzano E
    Br J Radiol; 2020 Nov; 93(1115):20200645. PubMed ID: 32822540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Results of Mean GTV Dose Optimized Robotic-Guided Stereotactic Body Radiation Therapy for Lung Tumors.
    Baumann R; Chan MKH; Pyschny F; Stera S; Malzkuhn B; Wurster S; Huttenlocher S; Szücs M; Imhoff D; Keller C; Balermpas P; Rades D; Rödel C; Dunst J; Hildebrandt G; Blanck O
    Front Oncol; 2018; 8():171. PubMed ID: 29868486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulmonary Oligometastases Treated by Stereotactic Body Radiation Therapy: A Nationwide Survey of 1,378 Patients.
    Niibe Y; Yamamoto T; Onishi H; Yamashita H; Katsui K; Matsumoto Y; Oh RJ; Aoki M; Shintani T; Yamada K; Kobayashi M; Ozaki M; Manabe Y; Yahara K; Nishikawa A; Kakuhara H; Yamamoto K; Inoue T; Takada YU; Nagata K; Suzuki O; Terahara A; Jingu K
    Anticancer Res; 2020 Jan; 40(1):393-399. PubMed ID: 31892592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic Body Radiation Therapy for Pulmonary Metastasis from Colorectal Adenocarcinoma: Biologically Effective Dose 150 Gy is Preferred for Tumour Control.
    Lee TH; Kang HC; Chie EK; Kim HJ; Wu HG; Lee JH; Kim KS
    Clin Oncol (R Coll Radiol); 2023 Jun; 35(6):e384-e394. PubMed ID: 37003842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing efficacy and safety of stereotactic body radiation therapy for oligometastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) wild type.
    Hu X; Li H; Liu H; Liu Z; Xia T; Zhang J; Wang Y
    Transl Cancer Res; 2021 Jan; 10(1):184-194. PubMed ID: 35116250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm.
    Su TS; Lu HZ; Cheng T; Zhou Y; Huang Y; Gao YC; Tang MY; Jiang HY; Lian ZP; Hou EC; Liang P
    BMC Cancer; 2016 Nov; 16(1):834. PubMed ID: 27809890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival and prognostic factors of pulmonary oligometastases treated with stereotactic body radiotherapy.
    Sharma A; Duijm M; Oomen-de Hoop E; Aerts JG; Verhoef C; Hoogeman M; Nuyttens JJ
    Acta Oncol; 2019 Jan; 58(1):74-80. PubMed ID: 30280633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significant Correlation Between Overall Survival and Mean Lung Dose in Lung Stereotactic Body Radiation Therapy (SBRT).
    Dupic G; Biau J; Molnar I; Chassin V; Dedieu V; Lapeyre M; Bellière-Calandry A
    Front Oncol; 2020; 10():1577. PubMed ID: 32850462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Planning Target Volume D95 and Mean Dose Should Be Considered for Optimal Local Control for Stereotactic Ablative Radiation Therapy.
    Zhao L; Zhou S; Balter P; Shen C; Gomez DR; Welsh JD; Lin SH; Chang JY
    Int J Radiat Oncol Biol Phys; 2016 Jul; 95(4):1226-35. PubMed ID: 27209498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analyses of the local control of pulmonary Oligometastases after stereotactic body radiotherapy and the impact of local control on survival.
    Yamamoto T; Niibe Y; Aoki M; Shintani T; Yamada K; Kobayashi M; Yamashita H; Ozaki M; Manabe Y; Onishi H; Yahara K; Nishikawa A; Katsui K; Oh RJ; Terahara A; Jingu K
    BMC Cancer; 2020 Oct; 20(1):997. PubMed ID: 33054721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic body radiotherapy for early-stage non-small cell lung cancer: clinical outcomes from a National Patient Registry.
    Davis JN; Medbery C; Sharma S; Perry D; Pablo J; D'Ambrosio DJ; McKellar H; Kimsey FC; Chomiak PN; Mahadevan A
    J Radiat Oncol; 2015; 4(1):55-63. PubMed ID: 25774243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-institution results of Stereotactic Body Radiation Therapy (SBRT) for treating adrenal gland metastases from liver cancer.
    Xu B; Zhao X; Chen D; Zhao W; Wang X; Ding C; Yuan Z; Zhang H
    BMC Cancer; 2023 Jan; 23(1):73. PubMed ID: 36681809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.